EFFICACY OF SEQUENTIAL THERAPY THERAPY FOR HELICOBACTER PYLORI ERADICATION IN DUODENAL ULCER PATIENTS

Nguyễn Công Long1,, Vũ Công Phong
1 Department of Gastroenterology and Hepatology, Bach Mai Hospital

Main Article Content

Abstract

Objective: A sequential treatment schedule has been reported to be effective, but studies published to date were performed in oversea. We undertook this study to determine whether these results could be replicated in Vietnam. Subjects and methods: Firty-one patients with duodenal ulcer with H. pylori positive were enrolled to a 14-day sequential regimen 40 mg of esomeprazole, 1 g of amoxicillin, each administered twice daily for the first 7 days, followed by 40 mg of esomeprazol, 500 mg of clarithromycin, and 500 mg of metronidazole, each administered twice daily for the remaining 7 days. Results: The eradication rate achieved with the sequential regimen was 82.4%. The incidence of minor side effects was 25.5%. Sequential therapy includes one additional antibiotic (metronidazole) that is not contained in standard therapy. Conclusions: Sequential therapy was significantly therapy for eradicating H. pylori infection.

Article Details

References

1. De Francesco, V., et al., Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther, 2004. 19(4): p. 407-14.
2. Vaira, D., et al., Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication - A randomized trial. Annals of internal medicine, 2007. 146: p. 556-63.
3. Adachi, K., et al., Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatment. Current Therapeutic Research, 2003. 64(7): p. 412-421.
4. Malfertheiner, P., et al., Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007. 56(6): p. 772-81.
5. Garza González, E., et al., [Helicobacter pylori erradication and its relation to antibiotic resistance and CYP2C19 status]. Rev Esp Enferm Dig, 2007. 99(2): p. 71-5.